NASDAQ:CARA Cara Therapeutics (CARA) Stock Price, News & Analysis → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free CARA Stock Alerts $0.35 -0.09 (-20.45%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.34▼$0.4650-Day Range$0.35▼$0.8352-Week Range$0.34▼$4.45Volume2.14 million shsAverage Volume471,090 shsMarket Capitalization$19.14 millionP/E RatioN/ADividend YieldN/APrice Target$3.93 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Cara Therapeutics alerts: Email Address Cara Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside1,023.8% Upside$3.93 Price TargetShort InterestHealthy5.05% of Float Sold ShortDividend StrengthN/ASustainability-1.39Upright™ Environmental ScoreNews Sentiment-0.57Based on 16 Articles This WeekInsider TradingSelling Shares$5,237 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.23) to ($0.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.24 out of 5 starsMedical Sector135th out of 915 stocksPharmaceutical Preparations Industry54th out of 430 stocks 4.0 Analyst's Opinion Consensus RatingCara Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageCara Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cara Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.05% of the float of Cara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCara Therapeutics has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Cara Therapeutics has recently decreased by 5.74%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCara Therapeutics does not currently pay a dividend.Dividend GrowthCara Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCara Therapeutics has received a 61.20% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Clinical research services for physical health" and "Opioid painkillers" products. See details.Environmental SustainabilityThe Environmental Impact score for Cara Therapeutics is -1.39. Previous Next 1.4 News and Social Media Coverage News SentimentCara Therapeutics has a news sentiment score of -0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Cara Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows6 people have added Cara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,237.00 in company stock.Percentage Held by InsidersOnly 3.10% of the stock of Cara Therapeutics is held by insiders.Percentage Held by Institutions44.66% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cara Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Cara Therapeutics are expected to grow in the coming year, from ($1.23) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cara Therapeutics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cara Therapeutics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCara Therapeutics has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cara Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover About Cara Therapeutics Stock (NASDAQ:CARA)Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Read More CARA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CARA Stock News HeadlinesJune 14 at 5:26 AM | americanbankingnews.comCara Therapeutics (NASDAQ:CARA) Downgraded by Canaccord Genuity Group to HoldJune 14 at 5:26 AM | americanbankingnews.comCara Therapeutics (NASDAQ:CARA) Downgraded to Hold at Needham & Company LLCJune 13 at 12:21 PM | benzinga.comThese Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'June 13 at 9:14 AM | americanbankingnews.comCara Therapeutics' (CARA) "Hold" Rating Reaffirmed at Canaccord Genuity GroupJune 13 at 8:44 AM | investorplace.comWhy Is Cara Therapeutics (CARA) Stock Down 27% Today?June 13 at 7:49 AM | americanbankingnews.comCara Therapeutics (NASDAQ:CARA) Rating Lowered to Neutral at HC WainwrightJune 13 at 7:14 AM | americanbankingnews.comCara Therapeutics (NASDAQ:CARA) Cut to "Hold" at Stifel NicolausJune 12 at 4:19 PM | reuters.comCara Therapeutics discontinues study on a neurological condition as drug failsJune 12 at 4:01 PM | globenewswire.comCara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia ParestheticaMay 29, 2024 | yahoo.comLaurel's Plan to Take Out Cara Maria Leads to a Stunning Blindside on 'The Challenge: All Stars' Season 4May 29, 2024 | yahoo.comWhy Laurel Stucky Is Coming for Cara Maria on The ChallengeMay 29, 2024 | msn.com5 Reasons Why Cara Delevingne Is Us Weekly’s Woman CrushMay 14, 2024 | finanznachrichten.deCara Therapeutics, Inc.: Cara Therapeutics Reports First Quarter 2024 Financial ResultsMay 14, 2024 | markets.businessinsider.comIn-Depth Examination Of 5 Analyst Recommendations For Cara TherapeuticsMay 13, 2024 | investorplace.comCARA Stock Earnings: Cara Therapeutics Misses EPS, Beats Revenue for Q1 2024May 13, 2024 | chron.comCara: Q1 Earnings SnapshotMay 13, 2024 | globenewswire.comCara Therapeutics Reports First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comCara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024May 2, 2024 | yahoo.comCara Maria Hatches a Revenge Plot on 'The Challenge: All Stars' Season 4May 1, 2024 | msn.comComedian Cara Connors on Coming Out, Being a “Sassy Gay Cowboy,” and Dating Gen ZApril 30, 2024 | yahoo.comTime to Meander Through Cara Delevingne’s Dating History 😬April 29, 2024 | yahoo.comNeighbours' Remi and Cara caught out over Felix and JJ secretApril 28, 2024 | msn.comCara Delevingne's House Fire Cause Still A Mystery As LAFD Closes InvestigationApril 26, 2024 | bizjournals.comCara Porto-Osborn of Young + Wright ArchitecturalApril 24, 2024 | finance.yahoo.comOruka Therapeutics Expands Leadership Team, Naming Joana Goncalves, MBChB, as Chief Medical OfficerSee More Headlines Receive CARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/15/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CARA CUSIPN/A CIK1346830 Webwww.caratherapeutics.com Phone(203) 406-3700Fax203-567-1510Employees55Year FoundedN/APrice Target and Rating Average Stock Price Target$3.93 High Stock Price Target$12.00 Low Stock Price Target$1.00 Potential Upside/Downside+1,023.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,510,000.00 Net Margins-723.49% Pretax Margin-723.49% Return on Equity-174.15% Return on Assets-105.26% Debt Debt-to-Equity RatioN/A Current Ratio5.38 Quick Ratio5.20 Sales & Book Value Annual Sales$20.97 million Price / Sales0.91 Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book0.33Miscellaneous Outstanding Shares54,680,000Free Float52,981,000Market Cap$19.14 million OptionableOptionable Beta0.79 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Christopher A. Posner (Age 54)President, CEO & Director Comp: $1.2MMr. Ryan D. Maynard (Age 55)Chief Financial Officer Comp: $511.7kDr. Joana Goncalves M.D. (Age 50)Chief Medical Officer Comp: $747.25kDr. Derek T. Chalmers D.Sc. (Age 60)Ph.D., Co-Founder & Senior Advisor Comp: $580.93kDr. Iris Francesconi Ph.D.Chief Strategy Officer & Head of Investor RelationsMr. Scott M. Terrillion (Age 61)Chief Compliance Officer, General Counsel & Corporate Secretary Comp: $689.63kMs. Beth Weinberg R.Ph.Senior Vice President of Regulatory Affairs & QAMr. Matthew MurphyManager of Investor RelationsMore ExecutivesKey CompetitorsTiziana Life SciencesNASDAQ:TLSACheckpoint TherapeuticsNASDAQ:CKPTEledon PharmaceuticalsNASDAQ:ELDNMilestone PharmaceuticalsNASDAQ:MISTVaccitechNASDAQ:VACCView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 149,809 shares on 5/10/2024Ownership: 4.539%Acadian Asset Management LLCSold 26,242 shares on 5/10/2024Ownership: 0.611%Marquette Asset Management LLCBought 94,238 shares on 5/7/2024Ownership: 0.172%Christopher PosnerSold 3,936 sharesTotal: $2,952.00 ($0.75/share)Rosalind Advisors Inc.Bought 1,548,893 shares on 4/25/2024Ownership: 2.833%View All Insider TransactionsView All Institutional Transactions CARA Stock Analysis - Frequently Asked Questions Should I buy or sell Cara Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are currently 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CARA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CARA, but not buy additional shares or sell existing shares. View CARA analyst ratings or view top-rated stocks. What is Cara Therapeutics' stock price target for 2024? 6 brokers have issued 1 year price objectives for Cara Therapeutics' shares. Their CARA share price targets range from $1.00 to $12.00. On average, they expect the company's share price to reach $3.93 in the next twelve months. This suggests a possible upside of 1,023.8% from the stock's current price. View analysts price targets for CARA or view top-rated stocks among Wall Street analysts. How have CARA shares performed in 2024? Cara Therapeutics' stock was trading at $0.7430 at the beginning of the year. Since then, CARA stock has decreased by 52.9% and is now trading at $0.35. View the best growth stocks for 2024 here. Are investors shorting Cara Therapeutics? Cara Therapeutics saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 2,300,000 shares, a decrease of 5.7% from the May 15th total of 2,440,000 shares. Based on an average trading volume of 384,500 shares, the days-to-cover ratio is presently 6.0 days. Approximately 5.1% of the company's stock are sold short. View Cara Therapeutics' Short Interest. When is Cara Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our CARA earnings forecast. How were Cara Therapeutics' earnings last quarter? Cara Therapeutics, Inc. (NASDAQ:CARA) issued its quarterly earnings data on Monday, May, 13th. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.18. The biopharmaceutical company had revenue of $2.14 million for the quarter, compared to analyst estimates of $2.25 million. Cara Therapeutics had a negative net margin of 723.49% and a negative trailing twelve-month return on equity of 174.15%. What ETF holds Cara Therapeutics' stock? Amplify Seymour Cannabis ETF holds 68,078 shares of CARA stock, representing 0.15% of its portfolio. What other stocks do shareholders of Cara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY). Who are Cara Therapeutics' major shareholders? Cara Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.54%), Rosalind Advisors Inc. (2.83%), Acadian Asset Management LLC (0.61%), Marquette Asset Management LLC (0.17%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Ryan D Maynard, Scott Terrillion and Thomas Charles Reilly. View institutional ownership trends. How do I buy shares of Cara Therapeutics? Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CARA) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHistoric NVIDIA partnership could send this tiny AI stock soaring...After striking partnerships with trillion-dollar chipmaker NVIDIA... ARM surged over 60% in a week... Who's...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
